These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3585 related items for PubMed ID: 2104626

  • 1. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 2. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [Abstract] [Full Text] [Related]

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 4. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 5. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 6. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 7. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C.
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [Abstract] [Full Text] [Related]

  • 8. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM, Karpas AE, Paulsen CA, Bremner WJ.
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [Abstract] [Full Text] [Related]

  • 9. Stimulation of sperm production by human luteinizing hormone in gonadotropin-suppressed normal men.
    Matsumoto AM, Paulsen CA, Bremner WJ.
    J Clin Endocrinol Metab; 1984 Nov; 59(5):882-7. PubMed ID: 6434586
    [Abstract] [Full Text] [Related]

  • 10. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [Abstract] [Full Text] [Related]

  • 11. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 12. Suppression of human spermatogenesis by testosterone implants.
    Handelsman DJ, Conway AJ, Boylan LM.
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
    [Abstract] [Full Text] [Related]

  • 13. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
    Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
    [Abstract] [Full Text] [Related]

  • 14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA, Wallace AM, Wu FC.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [Abstract] [Full Text] [Related]

  • 15. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [Abstract] [Full Text] [Related]

  • 16. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 18. Chronic human chorionic gonadotropin administration in normal men: evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man.
    Matsumoto AM, Karpas AE, Bremner WJ.
    J Clin Endocrinol Metab; 1986 Jun; 62(6):1184-92. PubMed ID: 3084535
    [Abstract] [Full Text] [Related]

  • 19. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
    Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM.
    J Androl; 2005 Jun; 26(3):405-13. PubMed ID: 15867009
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M, Nicol K, Petersen IB, Schou G.
    Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 180.